

Guido Baselli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2506977/guido-baselli-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

1,497
citations

16
h-index

38
g-index

43
ext. papers

2,277
ext. citations

7
avg, IF

4.13
L-index

#	Paper	IF	Citations
32	PSD3 downregulation confers protection against fatty liver disease.. <i>Nature Metabolism</i> , 2022 , 4, 60-75	14.6	1
31	Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of .. <i>Science Translational Medicine</i> , 2022 , 14, eabh3831	17.5	2
30	Factor VIII Epitope Analysis Using a Random Peptide Phage-Display Library Approach in the Sippet Cohort. <i>Blood</i> , 2021 , 138, 3176-3176	2.2	
29	SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. <i>Blood Transfusion</i> , 2021 , 19, 181-189	3.6	41
28	Impact of SARS-CoV-2 infection on the recovery of peripheral blood mononuclear cells by density gradient. <i>Scientific Reports</i> , 2021 , 11, 4904	4.9	5
27	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. <i>Cells</i> , 2021 , 10,	7.9	6
26	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , 2021 , 160, 1634-1646.e7	13.3	23
25	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. <i>Gut</i> , 2021 , 70, 180-193	19.2	39
24	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50
23	Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. <i>Pathology</i> , 2021 , 53, 462-469	1.6	4
22	Genetic insight into COVID-19-related liver injury. <i>Liver International</i> , 2021 , 41, 227-229	7.9	9
21	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 2712-2719	7.9	3
20	Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. <i>Nature Communications</i> , 2021 , 12, 4878	17.4	5
19	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1522-1534	59.2	913
18	PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. <i>Liver International</i> , 2020 , 40, 1130-1141	7.9	16
17	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemic. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1576-1578	9.5	6
16	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. <i>EBioMedicine</i> , 2020 , 52, 102658	8.8	36

15	Impact of natural neuromedin-B receptor variants on iron metabolism. <i>American Journal of Hematology</i> , 2020 , 95, 167-177	7.1	2
14	Association of ABO blood group and secretor phenotype with severe COVID-19. <i>Transfusion</i> , 2020 , 60, 3067-3070	2.9	16
13	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020 , 73, S13-S14	13.4	3
12	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. <i>Gut</i> , 2020 , 69, 1855-1866	19.2	34
11	PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis. <i>Journal of Hepatology</i> , 2019 , 70, e109-e110	13.4	4
10	gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. <i>Journal of Lipid Research</i> , 2019 , 60, 1144-1153	6.3	27
9	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 3682	4.9	42
8	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2310-2319.e6	6.9	42
7	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. <i>Scientific Reports</i> , 2019 , 9, 11585	4.9	44
6	Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges. <i>Journal of Hepatology</i> , 2019 , 71, 849-850	13.4	2
5	Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology. <i>Journal of Lipid Research</i> , 2019 , 60, 7-8	6.3	4
4	Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update. <i>Current Pharmaceutical Design</i> , 2018 , 24, 4566-4573	3.3	20
3	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018 , 2, 666-675	6	30
2	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2017 , 131, 1301-1315	6.5	38
1	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29